Geretsegger C, Greimel K V, Roed I S, Hesselink J M
Acute Treatment Services, Salzburg State Hospital, Austria.
Int J Eat Disord. 1995 May;17(4):359-63. doi: 10.1002/1098-108x(199505)17:4<359::aid-eat2260170407>3.0.co;2-c.
Seventeen women who met the criteria for bulimia nervosa (DSM-III-R) were treated for 4 weeks in an open trial with ipsapirone, a partial 5-HT1A agonist. Bulimic symptoms diminished in 66.6% of the patients after only 1 week of treatment, 93.3% showed a reduction of more than 50% of weekly binge eating attacks after 4 weeks. The mean frequency of binges was reduced by 81% at endpoint. Ipsapirone was well tolerated.
17名符合神经性贪食症（DSM-III-R）标准的女性参加了一项开放试验，接受了为期4周的ipsapirone（一种5-HT1A部分激动剂）治疗。仅治疗1周后，66.6%的患者贪食症状有所减轻，4周后，93.3%的患者每周暴饮暴食发作次数减少了50%以上。终点时暴饮暴食的平均频率降低了81%。Ipsapirone耐受性良好。
